Sinovac Biotech’s GB12 project has been included in Shenzhen’s strategic emerging industries support plan.
November 11, 2025
Source: drugdu
82
Shanghai Securities News China Securities(Reporter Zhao Binbin) On November 10, this reporter learned from Sinovac Biotech...It has been learned that the innovative drug developed by the company's wholly-owned subsidiary, Shenzhen Sinovac Biotech Co., Ltd.The GB12 project, "Key Technology Breakthrough for AI-Generated IL-4R/IL-31 Bispecific Antibody Innovative Drugs ," has been included in the list of projects proposed for funding under the first batch of strategic emerging industries support plans of the Shenzhen Development and Reform Commission in 2025.
This project aims to develop a bispecific antibody drug for atopic dermatitis (AD). The drug targets both the IL-4R and IL-31 pathways, targeting both inflammation and itching simultaneously. The project plans to submit new drug clinical trial applications in both China and the United States in the future.
https://finance.eastmoney.com/a/202511103560094614.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
